We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
3 watching
Current Price
$8.86
$0.28
(3.26%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
560.03M
52-Week High
22.41
52-Week Low
5.405
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization560.03M
52-Week High22.41
52-Week Low5.405
Average Volume0.21M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company s lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
24days ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following...
Business Wire
2 months ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to the public of $10.32 per share. All of the shares are to be sold by Edgewise Therapeutics. In addition, Edgewise Therapeutics has...
Business Wire
2 months ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common stock. In addition, Edgewise Therapeutics intends to grant the underwriters a 30-day option to purchase up to an...
Business Wire
5 months ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month interim results from the ongoing ARCH study, an open label...
Zolmax
5 months ago
Edgewise Therapeutics, Inc. (NASDAQ:EWTX Get Rating) General John R. Moore sold 7,125 shares of Edgewise Therapeutics stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $6.05, for a total value of $43,106.25. Following the completion of the sale, the...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$8.86
$0.28
(3.26%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00